Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Mindset Pharma Inc. is a drug discovery company that focuses on developing novel psychedelic and non-psychedelic medications to address neuropsychiatric and neurological disorders with unmet medical needs. The company recently entered into a definitive arrangement agreement with Otsuka Pharmaceutical Co., Ltd., signaling a significant acquisition worth approximately CAD $80 million. Mindset's innovative compounds and synthesis processes aim to revolutionize the treatment of psychiatric disorders, contributing to patient care on a global scale.
The Transaction, expected to close in October 2023, marks a strategic move by Otsuka to strengthen its presence in the psychiatry and neurology therapeutic areas. Mindset's shareholders will benefit from the all-cash acquisition, demonstrating a premium value of $0.75 per share. With a focus on maximizing the value of its assets and IP portfolio, Mindset's collaboration with Otsuka is poised to lead to groundbreaking advancements in patient treatment.
In pursuit of its mission to develop next-generation pharmaceutical assets, Mindset is dedicated to creating optimized and patentable psychedelic medicines, leveraging the therapeutic potential of psychedelic drugs. Through proprietary compounds, novel families of psychedelic compounds, and innovative synthesis processes, the company is at the forefront of advancing treatment options for neurological and psychiatric conditions.
Mindset Pharma (OTCQB: MSSTF), a leader in psychedelic drug discovery, announced its participation in three key conferences in June 2022. The virtual Grizzle Psychedelics Con 2022 is set for June 8, featuring a presentation by CEO James Lanthier at 10:15 a.m. ET. On June 9, Fiona Randall, SVP of Mindset, will engage in discussions at Charles River’s Symposium in San Francisco. Finally, on June 27, the company will attend the H.C. Wainwright Mental Health Conference in New York City. Mindset focuses on developing optimized psychedelic medicines for neurological and psychiatric disorders.
Mindset Pharma (OTCQB: MSSTF) is progressing its lead clinical candidate MSP-1014 towards human trials, following successful preclinical results. The company has appointed Clerkenwell Health as its Contract Research Organization to prepare for initial discussions with UK regulators. MSP-1014 shows improved efficacy and safety compared to psilocybin, targeting mood and substance misuse disorders. Manufacturing of pharmaceutical-grade MSP-1014 is underway, aiming for IND-enabling studies and clinical trials in 2023.
Mindset Pharma (OTCQB: MSSTF) has announced participation in two upcoming conferences aimed at advancing psychedelic medicine research. CEO James Lanthier will present on the importance of next-generation psychedelic drugs at the 2nd Annual Psychedelic Therapeutics & Drug Development Conference on May 23, 2022, in Arlington, VA. Additionally, both Lanthier and CSO Joseph Araujo will engage in a fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL. The company focuses on developing innovative psychedelic treatments for neurological and psychiatric disorders.
Mindset Pharma (CSE: MSET, OTCQB: MSSTF) has filed a new provisional patent application expanding its next-generation DMT and 5-MeO-DMT compounds, part of the Company’s ongoing strategy to enhance treatment options for mental health disorders. This patent covers new chemical entities that strengthen their psychedelic drug development pipeline. CEO James Lanthier emphasized the importance of differentiated treatments as more data from clinical trials emerges. This move positions Mindset favorably in the growing psychedelic market, which is experiencing increasing acceptance and potential regulatory changes.
Mindset Pharma (OTCQB: MSSTF) announced a new provisional patent application covering novel chemical entities in its next-generation DMT and 5-MeO-DMT platform. This development is part of the company's strategy to enhance its psychedelic medicine portfolio aimed at treating mental health disorders. The 'Family 4' compounds demonstrate promising efficacy and safety in pre-clinical models. As Mindset expands its IP footprint, it aims to expedite bringing innovative solutions to clinics, addressing the needs of patients waiting for transformative therapies.
Mindset Pharma Inc. (CSE: MSET, FSE: 9DF, OTCQB: MSSTF) announced CEO James Lanthier's participation in two upcoming virtual conferences. The Sequire Cannabis & Psychedelic Conference will take place on April 20, 2022, with Lanthier presenting at 2:30 p.m. ET. The KCSA Psychedelics Investor Conference is set for April 27-28, 2022, where he will speak on April 28 at 10:00 a.m. ET. Mindset focuses on developing next-generation psychedelic medicines for neurological and psychiatric disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) recently communicated positive developments to shareholders, emphasizing two key points. First, the partnership with MSRD, part of Otsuka's global pharmaceutical network, validates Mindset's approach to psychedelic drug development and secures ongoing funding. Second, the company aims to develop a diverse pipeline of psilocybin-inspired drug candidates, potentially leading to commercialization and increased revenue. Overall, Mindset's letter reflects a strong commitment to advancing its therapeutic portfolio and enhancing shareholder relations.
Mindset Pharma (CSE: MSET) (OTCQB: MSSTF) is advancing its psychedelic drug development through a new partnership with the McQuade Center for Strategic Research and Development (MSRD), part of Otsuka Pharmaceutical. This collaboration is a milestone for Mindset, providing $5 million in funding for clinical trials of its psilocybin and 5-MeO-DMT compounds. The company is focused on developing innovative therapies for mental health disorders, including Treatment-Resistant Depression, leveraging its novel Families of compounds, including MSP-1014.
Mindset Pharma (OTCQB: MSSTF) announced its participation in three upcoming investor conferences aimed at promoting its next-generation psychedelic medicines for neurological and psychiatric disorders. CEO James Lanthier and CSO Joseph Araujo will represent the company, with Araujo on the Psychedelics: Immunotherapy for the Mind panel at the 34th Annual Roth Conference from March 13-15, 2022. Lanthier will present at Oppenheimer’s Healthcare Conference on March 17, and a corporate presentation will be available during Maxim’s Virtual Growth Conference from March 28-30.
Mindset Pharma (OTCQB: MSSTF) announced significant findings under its Co-operative Psychedelics Evaluation Platform (COPE) program with InterVivo Solutions. New data on 5-MeO-DMT and first-generation psychedelics indicates differences in their mechanisms and increased bioavailability at higher doses. This research aids in benchmarking psychedelic drugs, enhancing preclinical evaluations for drug candidates. The COPE program aims to standardize assessments for next-generation psychedelic compounds, ultimately contributing to improved patentability and drug development.
FAQ
What is the market cap of Mindset Pharma (MSSTF)?
What is Mindset Pharma Inc. focused on?
What recent agreement did Mindset Pharma Inc. enter into?
How will the acquisition benefit Mindset Pharma Inc.'s shareholders?
What is the focus of Mindset Pharma Inc.'s drug development programs?
What is the expected timeline for the completion of the Transaction between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd.?
How does the collaboration between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd. contribute to patient care?
What sets Mindset Pharma Inc. apart in the pharmaceutical industry?
